Top-News

PREMIER ROYALTY News

Aktie
WKN:  A1J9WZ ISIN:  CA74057B1022
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
78,43 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
*Stand: 16.07.2013

PREMIER ROYALTY News

19.10.18 - PR Newswire
Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial
Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial - Sylentis has reached the target of recruiting patients for its Phase III trial "HELIX" for the ...
24.09.18 - PR Newswire
PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer
PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer PR Newswire
06.09.18 - PR Newswire
PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference
PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-​cell Lung Cancer During the IASLC World ...
03.08.18 - PR Newswire
The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin
The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin PR Newswire
31.07.18 - PR Newswire
PharmaMar kündet an, dass die ATLANTIS-Studie ihr Rekrutierungsziel erreicht hat
PharmaMar kündet an, dass die ATLANTIS-​Studie ihr Rekrutierungsziel erreicht hat PR Newswire
31.07.18 - PR Newswire
PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment
PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment PR Newswire
31.07.18 - PR Newswire
PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment
PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment PR Newswire
27.07.18 - PR Newswire
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe PR ...
27.07.18 - PR Newswire
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe PR ...
26.06.18 - PR Newswire
PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan
PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan PR Newswire
12.06.18 - PR Newswire
PharmaMar und Pint Pharma International unterzeichnen einen Kommerzialisierungs- und Vertriebslizenzvertrag für Aplidin®
PharmaMar und Pint Pharma International unterzeichnen einen Kommerzialisierungs- und Vertriebslizenzvertrag für Aplidin® PR Newswire
11.06.18 - PR Newswire
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International PR Newswire
11.06.18 - PR Newswire
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International PR Newswire
05.06.18 - PR Newswire
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin PR Newswire
05.06.18 - PR Newswire
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin PR Newswire
05.06.18 - PR Newswire
PharmaMar-Präsentation bei mündlicher Vortragssitzung auf ASCO: Bereinigtes Gesamtüberleben mit Plitidepsin aus ADMYRE-Studie
PharmaMar-​Präsentation bei mündlicher Vortragssitzung auf ASCO: Bereinigtes Gesamtüberleben mit Plitidepsin aus ADMYRE-​Studie PR Newswire
04.06.18 - PR Newswire
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-​cell Lung Cancer at ASCO 2018 PR Newswire
04.06.18 - PR Newswire
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018
PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-​cell Lung Cancer at ASCO 2018 PR Newswire
29.05.18 - PR Newswire
Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)
Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-​cell Lung Cancer (ATLANTIS) PR Newswire
17.05.18 - PR Newswire
PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018
PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018 PR Newswire

Newssuche

Videos

newspaper
17.05.24 +6,63%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »